SEQUA.BR Sequana Medical (Euronext) pre-market 20 Mar 2026: down 5.25%, watch cash

SEQUA.BR stock opened sharply lower in pre-market trade on 20 Mar 2026 after a weak session yesterday, trading at EUR 0.48 (previous close EUR 0.51, intraday low EUR 0.463). The main market move follows renewed investor focus on the company’s cash position and earnings due 25 Mar 2026. Sequana Medical NV (SEQUA.BR) reports results in five days, and investors will watch revenue trends, cash burn and guidance for the alfapump and DSR programs. Volume is elevated at 444,657 shares versus a 50-day average of 335,225 shares, signaling attention ahead of the call.

SEQUA.BR stock: earnings snapshot and calendar

Sequana Medical NV (SEQUA.BR) will announce results on 25 Mar 2026; the company lists on EURONEXT in Europe and operates in medical devices for fluid overload. Management is expected to update revenue mix for alfapump and DSR programs and provide guidance on commercial rollout in Germany and France.

Investors should note the last reported EPS is -1.23 and the trailing PE is -0.39, reflecting continued losses as the business scales. The upcoming release is the primary near-term catalyst for SEQUA.BR stock.

SEQUA.BR stock: recent price action and liquidity

Price sits at EUR 0.48 (current tick EUR 0.4785), down 5.25% today with intraday range EUR 0.463–0.51, and year-to-date down 20.25%. Trading volume is 444,657.00 shares versus average 335,225.00, a relative volume of 1.33, showing higher-than-normal activity ahead of earnings.

Market cap is EUR 35,661,616.00 with 74,527,934.00 shares outstanding; short-term volatility is high and liquidity is thin versus larger healthcare names, increasing execution risk for large orders.

SEQUA.BR stock: financials, valuation and cash metrics

Sequana reports negative profitability metrics: TTM net income per share -1.36, free cash flow per share -0.47, and cash per share 0.19. Book value per share is -1.02, and the current ratio is 0.20, highlighting a tight short-term liquidity position.

Valuation comparisons are difficult: price-to-book is -0.47 and price-to-sales is effectively 0.00 given minimal revenue per share. Analysts will focus on burn rate and any guidance or financing plans announced at the earnings report.

SEQUA.BR stock: technical read and market signals

Momentum indicators show weakness: RSI 33.84 (near oversold) and MACD near neutral, while the stock trades below both the 50-day average EUR 0.56 and 200-day average EUR 0.85. Bollinger bands (0.48–0.60) suggest the current price is near the lower band.

Short-term indicators (Stochastic %K 4.76, Williams %R -89.38) are deeply oversold, which can produce volatile rebounds around events like earnings but does not change the underlying liquidity and cash concerns.

Meyka AI rates SEQUA.BR with a score out of 100: grade and analyst view

Meyka AI rates SEQUA.BR with a score out of 100: 68.65 / 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model weights sector and industry comparisons, financial growth, key metrics, forecasts and analyst signals.

Third-party ratings show mixed signals: a company rating dated 19 Mar 2026 lists a C / Sell view driven by DCF and several valuation metrics, while some operational metrics (ROE) register positively. Investors should treat ratings as context, not guidance.

SEQUA.BR stock: what to watch at the earnings call

Key items to monitor on 25 Mar 2026 are: updated revenue cadence for alfapump and DSR, disclosed quarterly cash burn, any new reimbursement wins, and management’s plan for financing if cash runway is limited. Confirmation of commercial traction in Belgium, Germany or France would be constructive.

Also watch for adjusted EBITDA, order backlog commentary, and explicit guidance for 2026. Market reaction will hinge more on cash guidance and financing clarity than on near-term operating losses.

Final Thoughts

SEQUA.BR stock is trading at EUR 0.48 (exact tick EUR 0.4785) with pronounced pre-market weakness ahead of the 25 Mar 2026 earnings report. Operationally, Sequana Medical NV shows product-level progress but faces a constrained balance sheet: cash per share EUR 0.19, current ratio 0.20 and persistent negative FCF. Meyka AI’s forecast model projects EUR 0.74 for the next year. Compared to the current price of EUR 0.48, this implies an upside of 54.86%. Forecasts are model-based projections and not guarantees. The immediate trade is event-driven: if management provides clearer cash runway and tangible commercial milestones, upside could follow; if the company signals the need for dilutive financing, downside risk will likely accelerate. Use the earnings call to prioritise cash, guidance and reimbursement progress. For full company releases see the investor site source and news archive source. For our live SEQUA.BR page see Meyka SEQUA.BR page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.